NEWS

CURRENT ISSUE: AU Breast Cancer Research Review - Issue 80

In this edition:

View this issue online here.

-  Palbociclib for hormone-receptor+, HER2+ advanced breast cancer
-  Sacituzumab govitecan + pembrolizumab for advanced TNBC
-  TDP for HER2+ metastatic breast cancer
-  PROs for SERENA-6: camizestrant + CDK4/6 inhibitor in advanced ESR1-mutated breast cancer
-  Camizestrant + capivasertib for oestrogen receptor+, HER2– advanced breast cancer
-  Chemotherapy in lymph node-negative invasive papillary breast cancer
-  Extended endocrine therapy after adjuvant LHRH in premenopausal node+, hormone receptor+ breast cancer
-  Adding ipatasertib to dual anti-HER2 maintenance in PIK3CA-mutated HER2+ metastatic breast cancer
-  Sapacitabine + olaparib in BRCA1/2-mutated metastatic breast cancer
-  Neoadjuvant trastuzumab deruxtecan alone or followed by THP for high-risk HER2+ early breast cancer